SUPPRELIN LA
Post-LOEhistrelin acetate
NDASUBCUTANEOUSIMPLANT
Approved
May 2007
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPPRELIN LA is a histrelin acetate subcutaneous implant approved in 2007 for treating central precocious puberty (CPP) in children. It works as a GnRH agonist to suppress premature sexual development. The implant delivers continuous medication over 12 months, providing a non-invasive alternative to daily injections.
LOE ApproachingPost-LOE
Product faces patent expiration in June 2026 with moderate competitive pressure (25/100), signaling potential team restructuring and transition planning ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.